Enanta Pharmaceuticals Announces that AbbVie’s MAVIRET® (glecaprevir/pibrentasvir) Received Approval in U.S., E.U. and Japan for the 8-Week Treatment Most Major Genotypes of Chronic Hepatitis C Infection
Enanta Pharmaceuticals Announces that AbbVie’s MAVIRET® (glecaprevir/pibrentasvir) Received Approval in U.S., E.U. and Japan for the 8-Week Treatment Most Major Genotypes of Chronic Hepatitis C Infection